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ABSTARCT 
Guillain-Barre´ syndrome (GBS) is an acute onset, monophasic, paralytic 
disorder of the peripheral nervous system. The patho physiology of GBS 
involves an auto immune mediated attack on glycolipid components of 
nerves which has been supported by the frequent rise of anti ganglioside 
antibodies in acute sera of GBS patients. Anti ganglioside antibodies of IgG 
type, are found to be elevated in the sera from almost 60% of GBS patients. 
These anti ganglioside antibodies can be used for early detection of GBS 
because of their presence in the acute phase sera. Thereby they can be used 
as diagnostic markers of various GBS subtypes.It has been demonstrated that 
these antiganglioside antibodies are associated with poor prognosis in some 
studies. By conducting this study,we aimed to investigate the value of anti 
ganglioside antibody detection as a diagnostic and prognostic marker of 
GBS in acute phase. This study extends the previous findings on the 
relationship between antiganglioside antibodies and GBS. Though many 
studies on this topic are available from western countries, very few have 
been done in our country. Among the available studies , number of patients 
included in the study was low with occasional case reports of sero positivity. 
To overcome these limitations, this study was done to assess the anti 
ganglioside antibody positivity in GBS patients and its correlation with 
disease severity.From our study, we found out the following 
conclusions, 
 Assessment of antiganglioside antibody profile in GBS helps 
in the detection of disease in the early phase of illness. 
 Antiganglioside antibodies are useful in prognostication of 
GBS. 
 Antiganglioside antibodies are invariably present in severe 
GBS. 
 Larger sample size is required to make any definite 
meaningful correlation and utility of these antiganglioside 
antibodies in GBS. 
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INTRODUCTION 
                    Guillain-Barre´ syndrome (GBS) is an acute onset, monophasic, 
paralytic disorder of the peripheral nervous system. The term GBS is usually 
considered to be synonymous with acute inflammatory demyelinating 
polyradiculoneuropathy (AIDP), but with the growing recognition over the past 
few decades of variants, the diseases which fall under the rubric GBS has 
developed to include axonal variants and few restricted variants like  Miller Fisher 
syndrome (MFS).
1,2
 The clinical characteristics of Guillian  Baare syndrome were 
documented by Landry in 1859.
3
 After few decades Guillain, Barre´, and Strohl 
demonstrated the distinctive CSF characteristics of albumino cytological 
dissociation. The typical pathological findings of this illness including the 
peripheral nerve inflammatory changes had been described by Haymaker and 
Kernohan in 50 GBS patients.
4
 Waksman and Adams in their animal experiments 
demonstrated allergic neuritis in by injecting the peripheral nerve tissue with 
Freund adjuvant in the mid 1950s. Plasma exchange was found as an efficacious 
treatment option for GBS in 1980s.
5,6
 In1990s, efficacy of intravenous 
immunoglobulin (IVIg) in GBS was demonstrated.
7,8
  
                    The incidence of GBS has been reported as one to two per one lakh 
population. The general population had been shown to acquire the risk of GBS by 
one in thousand. GBS equally affects males and females. This disease can occur in 
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any age.
9,10 
 The onset of GBS is usually preceded by infectious illness. It usually 
has been shown to occur 10 – 14 days prior to the starting of GBS symptoms.11 
Among the antecedent infections, most commonly reported organisms are 
Campylobacter jejuni, Epstein-Barr virus, cytomegalovirus (CMV), influenza virus 
and Mycoplasma pneumonia. In addition to these infections, GBS has also been 
found to associated with immunization, surgery and parturition .
12
  
            The patho physiology of GBS involves an auto immune mediated attack on 
glycolipid components of nerves which has been supported by the frequent rise of 
anti ganglioside antibodies in acute sera of GBS patients. The antecedent microbial  
agents have epitopes on their surface which are similar to epitopes on the 
peripheral nerves resulting in the peripheral nerve components. Molecular mimicry 
between microbial and self antigens has been postulated as a pathogenic 
mechanism to account for the specific immune responses in postinfectious GBS.
13 
Carbohydrate components of gangliosides found on the peripheral nerve surface  
are molicular mimics of the lipooligosaccharides of Campylobacter jejuni.
14,15
 
During an otherwise mild infection , the antibodies which are meant to remove the 
microbial agents attach to carbohydrate component of nerves, causing injury to the 
peripheral nerves.
16
 The major sites of antibody attacks are the paranodal myelin, 
presynaptic component of the neuromuscular junction and the exposed axolemma 
at nodes of Ranvier.
11
 Macrophage induced destruction of myelin covering 
8 
 
occurs.
3,16
 Though the injury to myelin may affect the entire length of the nerve, 
the earliest pathological changes are seen at places where there is presence of  the 
week blood-nerve barriers.
11,17
 The pathogenic mechanism of axonal injury is 
thought to be due to complement activation causing membrane attack complex 
production causing  disintegration of the end portion of  axon.
11
  
             The pathological features vary according to the clinical variants of GBS. 
In AIDP,the characteristic pathologic picture has been completely known for more 
than 30 years, and is marked predominantly by inflammatory demyelinatory 
changes with focal and diffuse infiltration by lymphocytes and lipid-laden 
macrophages.
 
Though the major burden of disease tends to drop on the motor roots 
with the adjacent proximal plexuses, sensory motor nerve fibers also show some 
pathological changes. The earliest visible change in myelinated nerve fibers is the 
outer myelin layer vacuolation , which is preceded by activation of complement 
components along the complete outer Schwann cell surface of affected nerve 
fibers.It has been speculated that complement components get activated by 
antibody attachment to epitopes on the outer membrane of Schwann cells which 
leads to the complement activation initiating the cycle of myelin 
vacuolation,disintegration and ultimately phagocytosis by macrophages. 
Lymphocytic infiltration appear  later in the pathological process. The degree of 
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secondary axonal degeneration depends on the intensity of the inflammatory 
changes.
 18
  
             In contrast, the pathology of both AMAN and AMSAN variant of GBS is 
characterized by the absence of inflammatory changes. The major effect on nerve 
fibers is degeneration of axons, but the severity of pathologic change is variable. In 
AMAN variant of GBS, the primary immune attack is on the motor nodes of 
Ranvier.The pathological changes are also seen in motor roots, peripheral nerves, 
and  also in the intramuscular motor twigs. It has been proved that the distal 
pathology alone can explain majority of the clinical and electrophysiological 
characteristics of acute motor axonal neuropathy.
19,20 
 
              In AMSAN variant of GBS, the primary attack is on both the motor and 
sensory nerve nodes of Ranvier, but the sequence of pathological events leading to 
complement activation, macrophage infiltration and the axonal damage follow the 
similar chain as in acute motor axonal neuropathy variant of GBS.
19,20,21
 
          The GBS is clinically characterized by abrupt onset sensory symptoms. 
These sensory manifestations are often accompanied by or immediately followed 
by dysfunction of power. Patients are able to note the exact date of onset of motor 
and sensory dysfunction. The illness is characterized by its rapid progression, with 
around half of affected persons progressing to the clinical peak by approximately 
two weeks and around ninety percent of patients reach the nadir by about four 
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weeks. Neurological examination shows both distal and proximal weakness of 
symmetrical distribution. There may not be any sensory signs initially. Generalized 
absent or reduced jerks is the major neurological feature of the illness. Phrenic 
nerve involvement leading to diaphragmatic paralysis is also common. Around 30 
% GBS patients need respiratory support as a result of oropharyngeal or 
neuromuscular weakness.
22-27
 Autonomic disturbances in the form of tachycardia is 
seen in approximately 50 % of GBS patients. Though less common, more serious 
autonomic disturbances such as severe cardiac arrhythmias, labile blood pressure 
and gastrointestinal motility related complications may occur.
28-32
 
             CSF analysis and electrophysiological studies serve as supportive ancillary 
tests for GBS.Both these tests don‟t show any abnormal response initially. The 
restrictions of  these supportive tests at the starting  combined with the significance 
of timely intervention of GBS urges that the physician at times formulate the 
diagnosis based mainly on history and clinical details. The raised CSF protein 
content and acellular smear known as albumin cytological dissociation is seen on 
CSF studies in half of  patients; whereas,  elevated CSF protein content occurs in 
more than 90% of GBS patients at clinical nadir. CSF analysis need not be 
repeated if the first CSF analysis is normal with clearcut clinical possibility of 
GBS. CSF with cellular smear is not the feature of GBS . This feature may occur in 
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infectious (AIDS, Cytomegalovirus, Lyme), neoplastic, or sarcoidosis with  
polyradiculoneuropathy.
23
  
              Electrophysiological studies such as nerve conduction studies are done to 
keep up the clinical diagnosis that the acute weakness is because of  peripheral 
nerve involvement. Nerve conduction study of GBS patients often shows 
demyelination findings, such as markedly reduced conduction velocity, and 
prolonged CMAP latency and F-wave latency prolongation.
33
 Electrophysiological 
characteristics of acquired demyelination such as temporal dispersion ,conduction 
block, non uniform conduction velocity slowing) are predominantly helpful as 
these findings are distinctive of acquired demyelinating neuropathies of immune 
dysregulation. In early phase of GBS, prolonged F wave latencies are 
characteristically seen followed by prolonged distal CMAP latency with temporal 
dispersion .Whereas reduced nerve conduction velocities and conduction block are 
usually late signs in electrophysiological study of GBS. Another 
electrophysiological characteristic of this illness is „„sural sparing‟‟; that is, the 
presence of a normal sural study  in the presence of deranged upper limb sensory  
study. The sural sparing pattern is found in approximately 50-75 % of GBS 
patients done at the initial phase of illness. This characteristic pattern is highly 
unusual for neuropathies except GBS. In addition to these electro physiological 
features, other features consist of absent H-reflexes, reduced distal CMAP 
12 
 
amplitudes. It has been shown that the H-reflex was  characteristically absent in 
97% of GBS patients in the first week of illness. It should also be noted that motor 
nerve conduction findings are more often abnormal than that of sensory nerve 
study in early GBS. Blink reflex is usually abnormal in GBS patients with facial 
nerve involvement. Needle electromyography typically shows the feature of 
reduction in  motor unit action potential recruitment.
 34-36
 
         Magnetic resonance imaging  spine is not routinely indicated. However, it is 
mainly done to rule out other mimics, such as myelopathy or compressive and 
infiltrative lesions. Presence of enhancement of affected root and cranial nerve on 
MRI support the diagnosis of GBS.
37-39
 
             Plasmaphresis and intravenous immunoglobulins are effective treatment 
options for GBS if given during the initial few weeks of illness. In  GBS, plasma 
exchange is given as 50 mL/kg, on 5 cycles over one to two weeks.
6,7,8
 AAN 
guidelines stated that plasma exchange accelerate recovery in immobile patients 
with GBS who take treatment within 1 month of disease onset, and that plasma 
exchange accelerate recovery of mobile GBS patients who are examined within 14 
days. Therefore, AAN recommends plasma exchange for immobile GBS patients 
within 1month and for mobile GBS patients within 2 weeks of disease onset.
40
 The 
most advantageous number of PEs is not known, but many clinicians use the North 
American protocol which uses 200 to 250 mL/kg over 7 to 10 days. One study 
13 
 
showed that for adult GBS patients with mild illness, 2 exchanges were superior 
than none; and for patients with moderate illness or severe illness (on ventilator), 4 
exchanges were better than 2 and 6 exchanges were no superior than four. It has 
been demonstrated that the antiganglioside antibody levels fall after the first 2 
plasma cycles but not with further cycles.
41
 
        Although both these treatment options are mostly of similar efficacy, some 
studies have shown speed recovery with IVIg treatment when compared to plasma 
exchange. For  both older & childhood GBS cases , intravenous immunoglobulin is 
given as two gram per kg total dose divided over two to five days. The American 
academy of neurology guidelines concluded that IVIg is similarly effective in 
fastening recovery for GBS patients who require aid to walk if intravenous 
immunoglobulin is given within 2 weeks of the disease onset. The AAN guidelines 
recommend treatment with intravenous immunoglobulin for GBS patients who 
need aid to walk within two weeks or four weeks of GBS disease symptom onset.
40
 
             Anti ganglioside antibodies of IgG type, are found to be elevated in the 
sera from almost 60% of GBS patients.
42,43,44
 These anti ganglioside antibodies can 
be used for early detection of GBS because of their presence in the acute phase 
sera. Thereby they can be used as diagnostic markers of various GBS subtypes.It 
has been demonstrated that these antiganglioside antibodies are associated with 
poor prognosis in some studies. By conducting this study,we aimed to investigate 
14 
 
the value of anti ganglioside antibody detection as a diagnostic and prognostic 
marker of GBS in acute phase. 
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REVIEW OF LITERATURE 
 
          Guillain-Barré syndrome (GBS) was initially described in detail in 1859, by 
Jean Baptiste Landry, a French physician. However, Guillain, Barré, and Strohl 
gave the first widespread description, including clinical features,pathologic 
features and cerebrospinal fluid features. Additional information of similar cases 
were followed in detail. In 1949 a detailed clinicopathologic note of fifty cases of 
severe areflexic paralysis demonstrated that the clinical features may correlate with 
demyelinating or axonal changes.
4
 It is now obvious that Guillain-Barré syndrome 
is a syndrome which consists of several specific diseases,including the 
demyelinating form, namely acute inflammatory demyelinating polyneuropathy 
and axonal forms consists of acute motor axonal neuropathy and acute motor and 
sensory axonal neuropathy. Other clinical variants include the Miller Fisher 
syndrome characterized by the triad of ataxia ,ophthalmoplegia and areflexia, 
oropharyngeal variant, pure sensory neuropathy/ neuronopathy, pandysautonomia, 
and overlap syndromes.
2,45 
           The incidence of Guillain-Barré syndrome in Europe and North America 
is1-2/100,000/year in adults, and 0.4–1.4/100,000/year in children. Annual 
incidence of GBS from other regions ranges from as low as 0.40/100,000 in Brazil 
to 2.5/ 100,000 in Curacao.
46,47,48
 In particular, the relative frequency of axonal 
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type in comparison with the demyelinating variant varies by location. In North 
America and Europe, acute inflammatory demyelinating polyneuropathy is the 
major form, reporetd in up to 90% of Guillain-Barré syndrome patients.
49
 In 
contrast, axonal types account for 40 to 60% of patients in Asian countries.
50,51
 In 
North America, Miller Fisher syndrome is rare, accounting for 1 to 7% of all 
Guillain-Barré syndrome patients, but in Taiwan and Japan it is very common, 
accounting for even up to 19% of GBS patients.
52,53,54,55
 Around fifty percent of 
GBS patients have an precedent infection, usually less than 4 weeks prior to 
disease onset. The most common infections reported to be associated with GBS in 
adults are gastrointestinal (6–26%) and respiratory (22–53%) infections. 
Antecedent infections are usually more common in children (67–85%) with a 
larger frequency of respiratory (50–70%) than gastrointestinal (7–14%).The most 
commonly recognized organisms include Campylobacter jejuni, Epstein–Barr virus 
,Cytomegalovirus and Mycoplasma pneumoniae.
46,49
 Most cases of Guillain-Barré 
syndrome are sporadic, although rare epidemics have been noted after bacterial 
enteritis.
48
 
                 The initial manifestations of the GBS are numbness, pain, paresthesia, 
weakness or some mixture of these symptoms. The major feature is progressive 
bilateral and relatively symmetric limb weakness, and the weakness increases over 
a period of twelve hours to 28 days before reaching a plateau. Patients 
17 
 
characteristically have generalized absent or diminished reflexes.Among the 
available clinical diagnostic criteria Modified Asbury Cornbloth criteria is 
commonly used and is depicted in table 1.
22
 A history of  symptoms suggestive of 
upper respiratory or gastrointestinal infection three days to six weeks prior to the 
disease onset is not uncommon.
56 
                The differential diagnosis of GBS is wide, and detailed neurologic 
examination localizes the illness to the peripheral nerves.The presence of distal 
paresthesia increases the possibility that the likely diagnosis is the Guillain–Barré 
syndrome. If there is absent sensory involvement, disorders such as polio, 
botulism, generalized myasthenia gravis, dyselectrlytemia, or acute myopathy can 
be considered. Some features are common for both hypokalemia and GBS but the 
hypokalemia is commonly ignored in the differential diagnosis. In acute myopathy, 
deep tendon reflexes are usually preserved and serum creatine phospo kinase levels 
are elevated. If paralysis develops acutely with prominent bladder retention, MRI 
of the spine should be done, to rule out a compressive meylopathy. 
        Electrophysiological studies are useful in confirming the site of lesion and 
confirming the primary pathology whether axonal versus demyelinating type. Early 
findings are seen in over 80% of GBS patients, and most will become abnormal 
with follow up studies. Frequent early abnormalities include prolonged F-wave 
latencies, absent H-reflexes, and the sural sparing effect on sensory studies. The 
18 
 
sural sparing effect is characterized by the pattern of a normal sural sensory study 
with abnormal upper limb sensory response. Patients with primary axonal 
pathology may have early decrement in compound muscle action potentials 
amplitudes. It is essential that multiple nerves be studied. The major features of 
primary demyelination which include prolonged distal latencies, reduced motor 
conduction velocities, prolonged F minimum latencies, and partial block in 
conduction with abnormal temporal dispersion).These findings typically evolve 
over the initial one to two weeks after disease onset. Recognition of these electro 
physiological features is essential in confirming a diagnosis of GBS and in 
differentiation between various subtypes of GBS. There are many electro 
physiological published criteria for acute inflammatory demyelinating 
polyneuropathy and chronic inflammatory demyelinating polyneuropathy. The 
physician should be aware that these criteria were mainly developed for research 
purposes, and not all AIDP patients will fulfill them.
33-36 
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TABLE 1:DIAGNOSTIC CRITERIA FOR GBS 
Features required for diagnosis  
 
1. Progressive weakness in both 
arms and legs 
 
2. Areflexia  
 
Features strongly supporting 
diagnosis  
 
1. Progression of symptoms over 
days, up to four weeks 
 
2. Relative symmetry of symptoms 
 
3. Mild sensory symptoms or signs 
 
4. Cranial nerve involvement, 
especially bilateral weakness of 
facial muscles 
 
5. Recovery beginning two to four 
weeks after progression ceases 
 
6. Autonomic dysfunction 
 
7. Absence of fever at onset 
 
8. High concentration of protein in 
cerebrospinal fluid, with fewer 
than 10 cells per cubic millimeter 
 
9. Typical electrodiagnostic features 
Features excluding diagnosis 1. Diagnosis of botulism, 
myasthenia, poliomyelitis, or 
toxic neuropathy,abnormal 
porphyrin metabolism,recent 
diphtheria 
2. Purely sensory syndrome, without 
weakness 
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PATHOGENESIS: 
               The exact pathogenesis of GBS is not yet well elucidated, but it is 
presumed as an organ specific immune mediated illness resulting from a 
synergistic interaction of humoral and cell mediated immune responses to 
peripheral nerve antigens. Each GBS subtype has a relatively independent immune 
pathogenesis. 
 ACUTE INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (AIDP): 
                Demyelination is the characteristic pathological feature of AIDP. The 
primary target for immune attack is mainly within the myelin. AIDP is 
characterized by the presence of predominant lymphocytic infiltration in the 
peripheral nerves associated with the invasion by macrophages in the myelin 
sheath and Schwann cells. Thus cellular immunity plays a critical role in the 
pathogenesis AIDP. This commonest form of Guillain-Barré syndrome is 
pathologically characterized by the presence of typical patchy segmental 
demyelination of the peripheral nerves resulting from macrophage invasion of the 
myelin sheath. Experimental allergic neuritis (EAN) was first demonstrated in 
1955 by Waksman and Adams. This forms the basis as an animal model to 
investigate the mechanisms of AIDP. The major roles of T lymphocytes and 
macrophages have been shown by many studies including adoptive transfer 
21 
 
experimental allergic neuritis. These pathological features emphasize the 
predominant involvement of cellular immunity in the pathogenesis of AIDP.
57,58,59
 
              Autoreactive T-cells identify a specific auto antigen presented by MHC 
class II molecules. Activated T-lymphocytes cross the blood-nerve barrier and 
enter the peripheral nervous system causing activation of  macrophages leading to 
the enhancement of macrophage mediated phagocytic activity resulting in the  
production of and the release of cytokines and other toxic mediators which 
ultimately result in the extension of  demyelination and secondary axonal damage. 
ACUTE MOTOR AXONAL NEUROPATHY: 
                     This type of GBS is pathologically marked by axonal degeneration, 
which suggest the possible immune attack against the nerve axon. There may be 
reversible conduction block at the nodes of Ranvier. Among the precedent 
infections, C.jejuni is the commonest organism associated with AMAN. This   type 
of GBS has been found to associated with various anti-ganglioside antibodies 
which include GM1, GM1b, GD1a or GalNAc-GD1a.
62,63
 Many studies suggest 
that humoral immunity plays an important role in the pathogenesis of AMAN. 
"Molecular mimicry” plays an important role in the initiation of pathological 
events leading to AMAN. It was proved that some other preceding infectious 
organisms including EBV, CMV, Mycoplasma pneumoniae also have structural 
22 
 
similarity between their carbohydrate sequences (antigens) and  with that of 
peripheral nerve tissues.
64,65,66 
           This humoral immune response is characterized by the presence of auto 
antibodies which cross the blood-nerve barrier and causing axonal damage. This 
antibodies may be locally produced by B lymphocytes and causing direct axonal 
attack or through the activation of the complement system which ultimately result 
in resulting in predominant axonal damage with minimal demyelination. This 
axonal damage is histologically characterized by penetration of Schwann cell basal 
lamina by the macrophages thereby enter the periaxonal space,finally resulting in 
the axonal degeneration. This type of GBS is characterized by the absence of 
lymphocytic infiltration. Some studies demonstrated that even neuromuscular 
junction may play an important role as a site of   antibody action.
62,63
 
ACUTE MOTOR AND SENSORY AXONAL NEUROPATHY: 
               AMSAN is an  another subtype of GBS with axonal pathology sharing 
many similar clinical and pathological features with AMAN except that the 
patients have major sensory involvement in addition to motor involvement. Studies 
have shown that some of  anti-ganglioside antibodies (anti-GM1, anti-GM1b, and 
anti- GD1a IgG antibodies) are associated with this type of GBS.
21,67
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MILLER FISHER SYNDROME: 
              MFS is a rare variant of GBS characterized by the presence of elevated  
serum titers of Anti GQ1b and Anti GT1a antibodies which were consistently 
demonstrated in 90% and 100% of patients respectively. GQ1b is abundant in 
ocular muscle nerves, which may explain the vulnerability of the oculo motor 
system to immune mediated attack in these patients clinically characterized by the 
presence of ophthalmoplegia.
63
 
DISORDERS OF GBS SPECTRUM WITH ASSOCIATED ANTIGANGLIOSIDE 
ANTIBODIES: 
 
 
              
GBS
AIDP
NONE
AMAN
GM1, GD1a
AMSAN
GM1, GD1a
Pharyngeal–
cervical–
brachial 
weakness
GT1a > GQ1b 
>> GD1a
Acute motor-
conduction-
block 
neuropathy
GM1, GD1a
MFS
GQ1b, GT1a
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             Khalili-Shirazi et al did a prospective study with the objective of 
demonstrating the association between anti ganglioside antibody seropositivity and 
Guillan-Barré syndrome  after a recent cytomegalovirus  infection. In their study 
Enzyme linked immunosorbant assay (ELISA) was done on serum samples from 
14 patients with GBS with precedent cytomegalovirus infection and 12 without 
CMV infection, 17 patients with other neurological diseases, 11 patients with a 
recent CMV infection but without neurological involvement, 11 patients with 
recent Epstein-Barr virus infection but without neurological involvement, and 20 
normal control  subjects. They concluded that  anti GM2 antibodies are commonly 
associated with GBS with precedent CMV infection, but their relevance in 
pathogenesis is not exactly known. In this study they found out that it is unlikely 
that CMV infection and anti GM2 antibodies are exclusively responsible for the 
pathogenesis and there may be an additional factor   needed   to elicit GBS.
68
 
            Koga et al did a retrospective study on 602 GBS patients. Out of these, 15 
patients with bulbar involvement were included and serum antibodies against 
GM1, GM1b, GD1a, GalNAc- GD1a, GT1a, and GQ1b were examined in 13 of 
them. Serum anti ganglioside antibodies were found to be positive in eleven (85%) 
patients. IgG anti-GT1a  was positive in eight patients (62%) and anti-GM1b was 
positive in seven patients (54%) .Anti GM 1 antibody was negative in all the 
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patients. Some patients had  elevated  anti- GD1a and anti-GQ1b antibody titres, 
but most had high GM1b or GT1a antibody titres. Antecedent diarrhoea  was  
found in only one patient among the  five patients with high IgG antibody titre to 
GM1b or GT1a. Anti GT1a antibody was found in some patients with pharyngeal-
cervical brachial weakness .They also found that anti- GM1b and anti-GT1a 
antibodies were not associated with the presence of bulbar palsy. They observed 
complete recovery in sero negative patients. They concluded that the presence of  
serum IgG anti-GT1a and anti-GM1b antibodies support  the diagnosis of GBS and 
its variants when there is early bulbar involvement.
69
 
               In a study conducted by Caudie et al the anti-ganglioside antibodies IgG 
and IgM were analyzed in 249 GBS cases by the immune dot blot technique. The 
anti-ganglioside autoantibodies are positive in 123 patients. In 62% of cases, 
precedent infection was found. The most frequently identified infectious agents 
are Campylobacter jejuni in 24% of cases and cytomegalovirus (CMV) in 7% of 
cases. Vaccination is found to be associated with 2% of GBS. Thirty eight percent 
of sero positive patients had severe illness requiring ventilator requirement. Anti 
ganglioside antibodies were absent in 126 patients or 50% of GBS. This study 
group demonstrated that anti ganglioside antibodies are helpful in the diagnosis of 
GBS with atypical picture and in different electro clinical variants of GBS. This 
technique immune dot blot is simple and cheap. The search for these 
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autoantibodies has become necessary in GBS assessment. The antiGD1a and 
antiGM1 were positive in axonal variant of GBS, antiGQ1b antibodies are always 
associated ophthalmoplegia and antiGD1b are always associated with GBS sensory 
ataxia.
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            In a study conducted by Menon et al at National Institute of Mental Health 
and Neuroscience, Banglore, India twenty GBS patients were evaluated both 
clinically and electro physiologically  and antiganglioside antibody profile were 
done in all these patients. Three types of antiganglioside antibodies were assessed 
namely GM1, GD1a and GD1b. Out of 12 sero positive patients , two had all the 
three antibodies positive. They found no significant correlation between clinical, 
electro physiological and immunological features of GBS.
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TREATMENT: 
               Before considering the treatment options in GBS it is essential to estimate 
the severity of GBS. There are various scales available for the functional grading 
of disability in GBS. Among them the most widely used clinical severity 
assessment scale is the Hughes functional grading scale which is depicted in table 
2.
45
 For motor power grading, MRC sum score is commonly used which is 
depicted in table 3. All these assessment scales are useful in monitoring the 
treatment response, disease progression and in research studies. 
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TABLE 2:HUGH`S FUNCTIONAL GRADING SCALE 
                        SCORE               FEATURES 
0 Healthy 
1 Minor symptoms or signs, able to run 
2 Able to walk 5 m independently 
3 Able to walk 5 m with a walker or support 
4 Bed- or chair-bound 
5 Requiring assisted ventilation 
6 Death 
 
TABLE 3: MRC SUM SCORE 
Parts Right (x/5) Left(y/5) Total(x+y)/10 
Upper arm 
abductors 
   
Elbow flexors    
Wrist extensors    
Hip flexors 
 
   
Knee extensors    
 Foot dorsal 
flexors 
   
Total Score: Z/60 =                         
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TREATMENT SUB DIVISIONS IN GBS: 
 
SUPPORTIVE TREATMENT: 
                  Approximately one third of patients with severe GBS requires careful 
monitoring and requires mechanical ventilation. These patients must be carefully 
monitored in the intensive care setting particularly if there are autonomic sign, 
Hughes disability scale score ≥ 3 or <3 progressing. Intubation should be done if 
the patients show signs of bulbar dysfunction and aspiration.
62
 
 IMMUNOMODULATING TREATMENT: 
                       Effective immunomodulating treatment has been shown to be 
effective in reducing nerve damage, slow progression, and shorten hospitalization. 
Plasma exchange and intra venous immune globulins are the effective available 
immunomodulatory treatment options at present. Both plasma exchange and IVIg 
Supportive 
care
Pain 
management
Rehabilitation
Immuno
modulation
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have been shown to exhibit beneficial effects in GBS by causing significant 
alteration in disease course. Their effectiveness is almost similar and both found to 
be superior than supportive treatment alone. 
HIGH-DOSE IMMUNOGLOBULIN: 
                       The empirical dose of IVIG commonly used for GBS treatment is 
0.4 g/kg per day for five days. Six day course of IVIg has been shown to be 
superior in some studies but it was not statiscally significant. In pediatric GBS, 
IVIG  has been demonstrated to cause significant speedy recovery of illness and 
has also been found to be safe and effective. Because of its superior efficacy, 
safety, and availability IVIG stands as the treatment of choice in many GBS 
patients.
72,73 
                  The mode of action of IVIG have not been fully elucidated, but it is 
known that IVIG has multiple actions including suppression of antibody 
production, acceleration of antibody removal, neutralization of complement-
mediated damage, interference with antibody mediated cellular damage, 
modulation of nitric oxide synthesis and microglial function, direct action on T 
lymphocyte activation, cell adhesion inhibition, and initiation of apoptosis. Any or 
all of these may play a role in GBS treatment with IVIg.
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PLASMA EXCHANGE (PE): 
       Plasmaphresis is the first immune modulating therapy which was proved to be 
effective in GBS treatment. For mild GBS, Two exchanges are superior than none. 
For moderate and severe GBS four plasma exchanges are sufficient.If there is IVIg 
non responsiveness further plasma exchanges have not been found to be useful. 
The plasmaphresis regimen consists of exchange of approximately one plasma 
volume, 50 ml/kg. Many studies observed more side effects when fresh frozen 
plasma is used as the replacement fluid instead of albumin. Five percent albumin 
solution is routinely used as the replacement solution. If there is an increased risk 
of bleeding, fresh frozen plasma is beneficial than albumin.
75,76 
            There are many modifications of plasma exchange have been tried to 
improve its safety and effectiveness like immunoadsorption and double filtration 
techniques. These modifications are mainly done to prevent the risk of infection 
and allergic events. CSF filtration has also been tried in some studies. None of 
these techniques were found to be superior to plasmaphresis in terms of safety and 
efficacy. Combined treatment of plasma exchange and IVIG is not found to be 
better than either alone.
77
  
 CORTICOSTEROIDS: 
          Corticosteroids are commonly used variety of autoimmune disorders. But 
GBS is an autoimmune disorder with exception to this treatment rule. Steroids 
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have not been found to be useful in GBS in many studies and is not recommended 
in GBS and some authorities even contra indicate its use in GBS.
40
 
                 Pain is a major worrisome symptom observed in 89% of GBS patients; 
75% of the GBS patients were found to be benefitted by oral or parenteral opioids 
and 30% were managed with intravenous infusion of morphine. 10 percent of the 
patients required tricyclic antidepressants and a further 10% received 
carbamazepine for neuropathic pain. Epidural infusion of morphine has been found 
to effective in the control of severe pain in GBS.
78
 
                 Rehabilitation is essential for the speedy and effective recovery of GBS 
patients. Rehabilitation in the acute phase consists of gentle exercises which 
include isotonic, isometric, isokinetic exercises. During the disease course it should 
be focused on many measures such as proper limb positioning, nutrition, chest 
physiotherapy. On patients with significant disability orthotics should be used to 
prevent contractures.
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AIMS AND OBJECTIVES 
1. To assess the anti ganglioside antibody profile in GBS and its 
variants 
2. To assess the relevance of antibody profile in early diagnosis of 
GBS. 
3. To evaluate the prognosis of GBS using the antibody profile. 
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MATERIALS AND METHODS 
MATERIALS AND METHODS: 
                   Acute phase serum (within 72 hours of onset of symptoms) was 
collected from patients (since May 2012) who got admitted in Rajivgandhi 
Government General Hospital and Madras Medical College with  
(1) clinically defined syndrome comprising hyporeflexia, progressive 
symmetrical motor wakness and neurographic signs of motor and/or sensory 
peripheral neuropathy and  
(2) no alternative or contributing causes of neuropathy (e.g.,diabetes 
mellitus, vitamin deficiency, vasculitis, electrolyte abnormalities, exposure 
to neurotoxins) 
Detailed clinical and electrophysiological studies were done in all these patients. 
Using Euroline test kit by immuno blot method, IgG class of anti bodies against 7 
gangliosides (GM1, GM2, GM3, GD1a, GD1b, GT1b &GQ1b ) were tested in 
acute phase sera. The test kit contains test strips coated with parallel lines of 
purified antigens. The blot strips will be incubated in the first reaction step with 
diluted patient‟s serum. In case of positive samples, specific IgG antibodies will 
bind to the antigens coated in the strip. To detect the bound antibodies, a second 
incubation is done with enzyme labelled anti human IgG catalysing a colour 
reaction. 
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ETHICAL JUSTIFICATION: 
              A written informed consent was taken from the patient or caretakers after 
explaining the nature of study. The investigations planned were routinely indicated 
in the management of GBS. Three ml of blood was collected by venipuncture. The 
anti ganglioside antibody profile was done at free of cost. The information 
generated from this study helped in the appropriate management of cases. 
STATISTICAL ANALYSIS: 
               Based on data from published literature, which reported prevalence of  
anti ganglioside antibody positivity in GBS,  we conservatively assumed that 
around 60-70 % of our cohort would have seropositivity. To achieve ± 5% 
precision and 95% of confidence level, 40 sample size of GBS cases have been 
taken. For quantitative data, T test was applied. For qualitative test, chi square test 
was applied. For descriptive details, descriptive statistics was applied. Statistical 
analysis was conducted using SPSS 22.0 (SPSS, Chicago, IL, U.S.A).  
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RESULTS AND ANALYSIS 
DEMOGRAPHIC PROFILE: 
                   Out of 40 patients with GBS, 26 (65%) were male and 14(35%) were 
female.17 (42.5%) patients were in below 30 years age group and 23 (57.5%) were 
in above 30 years group. The mean age of our study cohort is 38.20 years with the 
standard deviation of 16.20 years. The median age of our study cohort is 36 
years.The socio economic status   of our study cohort is assessed by using the 
modified Kuppuswamy socio economic scale. The study cohort was classified into 
five socio economic classes on the basis of   this scale. None of our study group 
belong to upper class. 4 (10%) patients belong to upper middle class, 14 (35%) 
patients belong to lower middle class, 13 (32.5%) patients belong to upper lower 
class and 9 (22.5 %) patients belong to lower class of socio economic scale. The 
mean socio economic status of our study cohort is 3.67 with the standard deviation 
of  0.94 . The median socio economic class of study group is 4 (UPPER LOWER). 
The demographic profile of our study group is depicted in Table 4. 
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TABLE 4: DEMOGRAPHIC PROFILE OF THE STUDY GROUP 
 
VARIABLE          NUMBER MEAN MEDIAN S.D 
AGE 
AGE < 30 
years 
AGE>30 years 
N=40                               
17(42.5%) 
23(57.5 %) 
38.20 36.00 16.20 
SEX 
MALE 
FEMALE 
N=40 
26(65%) 
14(35%) 
 
- - - 
Socio 
Economic 
Status 
(Modified 
Kuppuswamy 
Scale) 
 
 
I.UPPER    - 0 (0%) 
II.UPPER MIDDLE -4 (10%) 
III.LOWER MIDDLE-14 (35%) 
IV.UPPER LOWER-13 (32.5 
%) 
V.LOWER-9 (22.5%) 
3.67 4.00 0.94 
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CLINICAL PROFILE OF STUDY GROUP: 
         Out of 40 GBS patients, 14 (35%) patients had antecedent infection. Among 
these 14 patients, 7 (17.5%) had respiratory infection and the remaining 7 (17.5 %) 
had gastro intestinal infection. Sensory symptoms were present in 10 (25%) 
patients. Bulbar symptoms were present in 25 (62.5%) patients. Areflexia was 
present in all our patients.  Ophthalmoplegia was present in 2 (5 %) patients. 
Autonomic signs were present in 12 (30 %) patients. The clinical features of  our 
study group is depicted in table 5. 
TABLE 5: CLINICAL PROFILE OF STUDY GROUP 
 
                   VARIABLE 
                                                              
FREQUENCY 
 
PERCENTAGE 
Antecedent Infection 
Respiratory Infection 
Gastro Intestinal Infection (Diarrhea) 
14 
7 
7 
35 
17.5 
17.5 
Sensory symptoms 10 25 
Ophthalmoplegia 2 50 
Areflexia 40 100 
Bulbar Symptoms 25 62.5 
Autonomic signs 12 30 
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ELECTRO PHYSIOLOGICAL PROFILE OF STUDY GROUP: 
             Out of 40 GBS patients, distal motor latencies were prolonged in 33 
(82.5%) patients. Compound Motor Action Potential amplitude were reduced in 19 
(47.5%) patients. Motor conduction velocities were decreased in 26 (65%) patients. 
F wave latency was prolonged in 36 (90 %) patients. On sensory conduction study, 
sensory nerve action potential amplitude was decreased in 15 (37.5%) patients. On 
the basis of clinical and electrophysiological analysis, our study group was divided 
into four GBS subtypes namely AIDP, AMAN, AMSAN and MFS. Out of 40 GBS 
patients, 15 (37.5 %) patients were AIDP, 13 (32.5 %) patients were AMAN, 10 
(25 %) patients were AMSAN and 2 (5 %) patients were MFS. 
The electrophysiological features of our study group is depicted in table 6. 
TABLE 6: ELECTRO PHYSIOLOGICAL PROFILE OF STUDY GROUP 
VARIABLE FREQUENCY PERCENTAGE 
Prolonged DL 33 82.5 
Reduced CMAP 19 47.5 
Reduced CV 26 65 
Prolonged F Latency 36 90 
Reduced SNAP Amplitude 15 37.5 
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CLINICAL DISEASE SEVERITY PROFILE OF STUDY GROUP: 
            The disease severity of our study group was analyzed by using the 
following parameters namely time to peak illness (time taken for the illness to 
reach clinical nadir) in days, duration of illness in days, MRC sum score at 
admission and discharge, Hugh score at admission and discharge. The mean time 
taken for the illness to reach the nadir was 6.37 days with the standard deviation of 
2.05 days. The median time to peak is 6 days. The mean duration of illness is 36.25 
days with the standard deviation of 11.41 days. The mean MRC sum score at 
admission was 22.4 with the standard deviation of 13.58. The mean MRC sum 
score at discharge was 45.3 with the standard deviation of 6.13. The median MRC 
sum score at admission and discharge were 41 and 24 respectively. The mean 
Hugh score at admission was 4.42 with the standard deviation of 0.55. The mean 
Hugh score at discharge was 3.25 with the standard deviation of 0.49. The median 
Hugh score at admission and discharge was 4 and 3 respectively. 
The clinical severity profile of our study group is depicted in table 7. 
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TABLE 7: CLINICAL DISEASE SEVERITY PROFILE OF STUDY GROUP 
VARIABLE MEAN MEDIAN S.D 
Time to Peak (In 
days) 
6.37 6.00 2.05 
Duration of illness 
(In days) 
36.25 41.00 11.41 
Admission MRC 
score  
22.4 24.00 13.58 
Discharge MRC 
Score 
45.3 46.00 6.13 
Admission Hugh 
Score 
4.42 4.00 0.55 
Discharge Hugh 
Score 
3.25 3.00 0.49 
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IMMUNOLOGICAL PROFILE IN GBS SUBTYPES: 
               Out of 40 patients with GBS 29 (72.5%) patients showed anti ganglioside 
antibody positivity. Among 15 patients with AIDP, 12 (80%) patients were 
seropositive. Among 13 patients with AMAN, 11 (85%) were seropositive. Among 
10 patients with AMSAN, 4 (10%) patients were seropositive. Among 2 MFS 
patients both (100 %) were seropositive. 
                 Anti GM1 ganglioside antibody was positive in 14 patients of GBS 
which include 6 AIDP patients, 7 AMAN patients and one AMSAN patient. Anti 
GM2 ganglioside antibody was positive in 19 patients of GBS which include 10 
AIDP patients, 7 AMAN patients and 2 AMSAN patients. Anti GM3 ganglioside 
antibody was positive in 12 patients of GBS which include 5 AIDP patients, 5 
AMAN patients and 2 AMSAN patients. Anti GD1a ganglioside antibody was 
positive in 6 patients of GBS which include 4 AIDP patients, one AMAN patient 
and one AMSAN patient. Anti GD1b ganglioside antibody was positive in 2 
patients of GBS which include one AIDP patient and one AMSAN patient. Anti 
GT1b ganglioside antibody was positive in one GBS patient which is a case of 
AMAN. Anti GQ1b antibody was positive in 2 GBS patients who were MFS. 
The immunological profile of our study group is depicted in table 8. 
   
44 
 
 TABLE 8: IMMUNOLOGICAL PROFILE IN GBS SUBTYPES 
GBS 
TYPE 
Antiganglioside 
Antibody 
positivity 
GM1 GM2 GM3 GD1a GD1b GT1b GQ1b 
AIDP 12(15) (80 %) 6 10 5 4 1 0 0 
AMAN 11(13) (85%) 7 7 5 1 1 1 0 
AMSAN 4(10) (40%) 1 2 2 1 0 0 0 
MFS 2(2) (100 %) 0 0 0 0 0 0 2 
TOTAL 29(40) (72.5%) 14 19 12 6 2 1 2 
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TREATMENT DETAILS IN STUDY GROUP: 
           Among 40 GBS patients, 22 (55%) patients required ventilator support. 
Twenty eight patients (70%) received intra venous immunoglobulin. Plasma 
exchange was done in 17 (42.5%) patients.  
The treatment details of our study group is depicted in table 9. 
 
TABLE 9: TREATMENT DETAILS IN STUDY GROUP 
TREATMENT NUMBER PERCENTAGE 
Ventilation 22 55 
IvIg 28 70 
Plasmaphresis 17 42.5 
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CLINICAL CORRELATION OF IMMUNOLOGICAL PROFILE: 
                 With regard to age, anti ganglioside antibodies were positive in 12 
patients of below 30 years age group and in 17 patients of above 30 years age 
group. These ganglioside antibodies were negative in 5 patients of below 30 years 
age group and in 6 patients of above 30 years age group. There is statistically 
significant higher antiganglioside antibody positivity in above 30 years age group. 
                 With regard to sex, antiganglioside antibodies were positive in 19 males 
and in 10 females. These antiganglioside antibodies were negative in 7 males and 
in 4 females. There is statistically significant higher antibody positivity in males. 
                 With regard to antecedent infection, antiganglioside antibodies were 
positive in 12 patients and negative only in 2 patients. There is statistically 
significant higher antibody positivity in patients with antecedent infections. 
                   With regard to bulbar symptoms, anti ganglioside antibodies were 
positive in all 25 patients with bulbar symptoms. There is statistically significant 
anti ganglioside antibody positivity in GBS patients with bulbar symptoms. 
                     With regard to autonomic signs, anti ganglioside antibodies were 
positive in all 12 patients with autonomic signs. There is statistically significant 
higher antibody positivity in GBS with autonomic signs.The clinical correlation of 
immunological profile is depicted in table 10. 
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TABLE 10: CLINICAL CORRELATION OF IMMUNOLOGICAL 
PROFILE 
VARIABLE ANTIBODY 
POSITIVE 
ANTIBODY 
NEGATIVE 
SIGNIFICANCE 
        (P Value) 
AGE 
AGE <30 yrs 
AGE >30 yrs 
 
12 
17 
 
5 
6 
 
0.05 
SEX 
MALE 
FEMALE 
 
19 
10 
 
7 
4 
 
0.01 
ANTECEDENT 
INFECTION 
YES 
NO 
 
 
12 
17 
 
 
2 
9 
 
 
0.01 
BULBAR 
SYMPTOMS 
YES 
NO 
 
 
25 
4 
 
 
0 
11 
 
 
0.01 
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AUTONOMIC 
SIGNS 
YES 
NO 
 
 
12 
17 
 
 
0 
11 
 
 
0.01 
 
CLINICAL SEVERITY CORREALTION WITH IMMNOLOGICAL 
PROFILE:  
                 Among the 29 sero positive patients, 27 patients reached the peak of 
illness in less than one weak duration whereas only 2 seronegative patients reached 
the nadir in less than one weak. There is statistically significant higher antibody 
positivity in patients who reach the clinical nadir in less than one weak. 
                 Among the 29 sero positive patients, 28 had the duration of illness lasted 
for more than one month and only one patient recovered within one month period. 
There is statistically significant higher antibody positivity in patients with longer 
duration ( more than a month) of illness. 
                 Among the 29 sero positive patients, 21 patients required ventilator 
support, whereas 8 patients did not require ventilator support. There is statistically 
significant higher antibody positivity in GBS patients who require ventilator 
support. 
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                  Among the 29 sero positive patients, 28 patients had MRC sum score of 
less than 30 at admission where as only one patient had the score of more than 
30.There is statistically significant higher antibody positivity in patients with low 
MRC sum score ( less than 30) at admission. 
               The correlation between the clinical and immunological profile of our 
study group is depicted in table 11.  
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TABLE 11: CLINICAL SEVERITY CORREALTION WITH 
IMMNOLOGICAL PROFILE 
VARIABLE ANTIBODY 
POSITIVE 
ANTIBODY 
NEGATIVE 
SIGNIFICANCE 
TIME TO PEAK 
< 7 days 
>7 days 
 
27 
2 
 
2 
9 
 
0.01 
DURATION OF 
ILLNESS 
<4 weeks 
>4 weeks 
 
 
1 
28 
 
 
10 
1 
 
 
0.01 
VENTILATION 
YES 
NO 
 
21 
8 
 
1 
10 
 
0.01 
ADMISSION 
MRC 
SUMSCORE  
<30 
>30 
 
 
 
28 
1 
 
 
 
 
 
0 
11 
 
 
 
0.01 
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DISCUSSION 
                     Pervious documented studies has demonstrated that at least half of  
GBS patients showed anti ganglioside antibody positivity during the acute phase of 
illness.
70
 Our study showed 72.5 % antibody positivity in the acute phase of illness. 
This finding correlates well with the previous research reports. Among the 
techniques used in antibody analysis, none is found superior to other. In our study 
ELISA was used as in many previous studies. This high antibody positivity in our 
cohort can be explained by two things. First it has been proved that antiganglioside 
antibody positivity is more common in GBS with preceding infections. In our 
study 14 patients had the history of precedent infection. In our part of country 
respiratory and gastro intestinal infections are common because of poor hygiene 
and sanitation. This may account for the higher sero positive rates in our study 
group. Secondly, many studies found an association between the severity of illness 
and antiganglioside antibody positivity.
70,71
 Though, our cohort has a mixture of  
population with variable disease severity, severe illness was found in many 
patients. This higher percentage of very severe illness group might have 
contributed this high degree of sero positivity in our study group. 
                    Our study has shown significant sero positivity in patients with 
antecedent infections. This has been very well demonstrated in many of the 
previous studies.
68,69
 This could be explained by the presumed pathogenic role of 
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molecular mimicry between the micro organisms and the gangliosides of 
peripheral nervous tissue. Our cohort had equal percentage of respiratory and 
gastro intestinal infections preceding GBS. The most common infections reported 
to be associated with GBS in adults are gastrointestinal (6–26%) and respiratory 
(22–53%) infections. Antecedent infections are usually more common in children 
(67–85%) with a larger frequency of respiratory (50–70%) than gastrointestinal (7–
14%). The most common organism found to be associated with GBS is 
campylobacter jejuni.
46-49
 In our study search for micro organisms could not be 
done because of limited resources. 
              Previous studies have shown strong positive correlation between the 
disease severity and anti ganglioside antibody positivity.
68-71
 Our study also 
demonstrated the similar phenomenon. In our study among the 29 sero positive 
patients, 27 patients reached the peak of illness in less than one weak duration 
whereas only 2 seronegative patients reached the nadir in less than one weak. 
There is statistically significant higher antibody positivity in patients who reach the 
clinical nadir in less than one weak. Now it has been clear that sero positive 
patients usually follow a severe course of illness with rapid onset peak illness. The 
MRC sumscore of our antibody positive group was significantly lower than that of 
sero negative group. This could be due to severe motor impairment in sero positive 
group when compared to less severe motor involvement in sero neagative group. 
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             Our study has shown significantly higher antibody positivity in patients 
with bulbar and autonomic involvement.
69
 This finding has been documented in 
many previous studies. Our cohort had two patients with Miller Fisher syndrome. 
Both of them showed anti GQ1b antibody positivity. Anti-GQ1b IgG antibodies 
are found to be highly sensitive and specific of MFS. It has also been found in 
some patients with AIDP with acute ophthalmoplegia. Some researchers suggest 
that anti- GQ1b IgG antibodies may play a significant role in the development of 
typical clinical signs seen in MFS. 
                  Most of our antibody positive patients required mechanical ventilation 
as a result of severe illness. The sero positive group took longer than usual time for 
recovery when compared to sero negative patients. The Hugh score has been used 
as a disability assessment score in our study like in many previous studies. This 
score was significantly high with the sero positive patients. There was no 
significant improvement in the muscle power and Hugh score was observed in 
antibody positive group. 
                    This study extends the previous findings on the relationship between 
antiganglioside antibodies and GBS. Though many studies on this topic are 
available from western countries, very few have been done in our country. Among 
the available studies , number of patients included in the study was low with 
occasional case reports of sero positivity. To overcome these limitations, this study 
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was done to assess the anti ganglioside antibody positivity in GBS patients and its 
correlation with disease severity. 
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                                                CONCLUSIONS 
1. Assessment of antiganglioside antibody profile in GBS helps in the 
detection of disease in the early phase of illness. 
2. Antiganglioside antibodies are useful in prognostication of GBS. 
3. Antiganglioside antibodies are invariably present in severe GBS. 
4. Larger sample size is required to make any definite meaningful 
correlation and utility of these antiganglioside antibodies in GBS. 
 
 
 
 
 
 
 
 
 
 
60 
 
BIBLIOGRAPHY 
 
1. Levin KH. Variants and mimics of Guillain Barre´ syndrome. Neurologist 
2004;10:61–74. 
2. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of 
ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57–65. 
3. Prineas JW. Pathology of the Guillain-Barre´ syndrome. Ann Neurol 
1981;9:6–19. 
4. Haymaker WE, Kernohan JW. The Landry-Guillain-Barre´syndrome: 
clinicopathologic report of 50 fatal cases and a critique of the literature. 
Medicine 1949;28:59–141. 
5. Efficiency of plasma exchange in Guillain-Barre´ syndrome: role of 
replacement fluids. French Cooperative Group on Plasma Exchange in 
Guillain-Barre´ Syndrome. Ann Neurol 1987;22:753–761. 
6. Plasmapheresis and acute Guillain-Barre´ syndrome. The Guillain-Barre´ 
Syndrome Study Group. Neurology 1985;35:1096–1104. 
7. van der Meche´ FG, Schmitz PI. A randomized trial comparing intravenous 
immune globulin and plasma exchange in Guillain-Barre´ syndrome. Dutch 
Guillain- Barre´ Study Group. N Engl J Med 1992;326:1123–1129. 
61 
 
8. Randomised trial of plasma exchange, intravenous immunoglobulin, and 
combined treatments in Guillain-Barre´syndrome.Plasma Exchange/ 
Sandoglobulin Guillain-Barre´Syndrome Trial Group. Lancet 
1997;349:225–230. 
9. Alter M. The epidemiology of Guillain-Barre´syndrome.Ann Neurol 
1990;27(Suppl):S7–S12. 
10. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre´ 
syndrome. J Infect Dis 1997;176(S2):S92–S98. 
11. Willison HJ. The immunobiology of Guillain-Barre´ syndromes. J Peripher 
Nerv Syst 2005;10:94–112. 
12. Jacobs BC, Rothbarth PH, van der Meche´ FG, et al. The spectrum of 
antecedent infections in Guillain-Barre´ syndrome: a case-control study. 
Neurology 1998;51:1110–1115. 
13. Rose, N.R. The role of infection in the pathogenesis of autoimmune disease. 
Semin Immunol. 1998;10:5–13. 
14. Willison HJ. Ganglioside complexes as targets for antibodies in Miller 
Fisher syndrome. J Neurol Neurosurg Psychiatry 2006;77:1002–1003. 
15. Sheikh KA, Nachamkin I, Ho TW, et al. Campylobacter jejuni lipo 
polysaccharides in Guillain-Barre´ syndrome: molecular mimicry and host 
susceptibility. Neurology 1998;51:371–378. 
62 
 
16. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann 
cell surface in acute inflammatory demyelinating polyneuropathy. Ann 
Neurol 1996;39:625– 635. 
17. Olsson Y. Topographical differences in the vascular permeability of the 
peripheral nervous system. Acta Neuropathol 1968;10:26–33. 
18. Asbury AK, Arnason BG, Adams RD.The inflammatory lesion in idiopathic 
polyneuritis:Its role in pathogenesis.Medicine 1969;48:173-216. 
19. Hafer-Macko C, Hsieh ST, Li CY, et al. Antibody and complement mediated 
attack on axolemma in acute motor axonal neuropathy. Ann Neurol 
1996;40:635-644. 
20. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor 
axonal neuropathy pattern of the Guillain-Barre syndrome. J Neurocytol 
1996;25:33-51. 
21. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal 
Guillain-Barre syndrome. Ann Neurol 1996;39:17-28. 
22. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for 
Guillain-Barre´ syndrome. Ann Neurol 1990;27(suppl):S21–S24. 
23. Ropper AH. The Guillain-Barre´ syndrome. N Engl J Med 1992;326:1130–
1136. 
63 
 
24. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with 
Guillain-Barre´ syndrome. Arch Neurol 2005;62:1194–1198. 
25. Gracey DR, McMichan JC, Divertie MB, Howard FM Jr.Respiratory failure 
in Guillain-Barre´ syndrome: a 6-year experience. Mayo Clin Proc 
1982;57:742–746. 
26. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. 
Anticipating mechanical ventilation in Guillain-Barre´ syndrome. Arch 
Neurol 2001;58:893–898. 
27. Massam M, Jones RS. Ventilatory failure in the Guillain-Barre´ syndrome. 
Thorax 1980;35:557–558. 
28. Lichtenfeld P. Autonomic dysfunction in the Guillain-Barre´syndrome. Am 
J Med 1971;50:772–780. 
29. Zochodne DW. Autonomic involvement in Guillain-Barre´syndrome: a 
review. Muscle Nerve 1994;17:1145–1155. 
30. Truax BT. Autonomic disturbances in the Guillain-Barre´syndrome. Semin 
Neurol 1984;4:462–468. 
31. Tuck RR, McLeod JG. Autonomic dysfunction in Guillain-Barre´ syndrome. 
J Neurol Neurosurg Psychiatry 1981;44:983–990. 
32. Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EF. Adynamic ileus 
in severe Guillain-Barre´ syndrome. Muscle Nerve 2001;24:963–965. 
64 
 
33. Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating 
polyneuropathies: clinical and electrodiagnostic features.Muscle Nerve 
1989;12:435–451. 
34. Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic 
abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. 
Muscle Nerve 1985;8:528–539. 
35. Ropper AH, Wijdicks EF, Shahani BT. Electrodiagnostic abnormalities in 
113 consecutive patients with Guillain-Barre´ syndrome. Arch Neurol 
1990;47:881–887. 
36. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-
Barre´ syndrome. Arch Neurol 2001;58:913–917. 
37. Crino PB, Zimmerman R, Laskowitz D, Raps EC, Rostami AM. Magnetic 
resonance imaging of the cauda equina in Guillain-Barre´ syndrome. 
Neurology 1994;44:1334–1336. 
38. Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of 
MRI lumbosacral nerve root enhancement in acute Guillain-Barre´ 
syndrome. Neurology 1996;47:813–817. 
39. Weiss MD. Root enhancement in GBS. Neurology 1997;48:1477. 
40. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: 
immunotherapy for Guillain-Barre´ syndrome: report of the Quality 
65 
 
Standards Subcommittee of the American Academy of Neurology. 
Neurology 2003;61:736–740. 
41. Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed 
to reduce immunoglobulin in Guillain-Barre´ syndrome. Neurology 
1998;51:875–877. 
42. Van Doorn P, Ruts L, Jacobs B. Clinical features, pathogenesis,and 
treatment of Guillain-Barre´ syndrome. Lancet Neurol 2008;7:939–950. 
43. Willison H. J, Yuki N. Peripheral neuropathies and antiglycolipid antibodies. 
Brain 2002;125:2591–2625. 
44. Kusunoki S, Kaida K, Ueda M.Antibodies against gangliosides and 
ganglioside complexes in Guillain-Barre´ syndrome: new aspects of 
research. Biochim. Biophys. Acta 2008;1780:441–444.  
45. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 
2005;366(9497):1653–1666. 
46. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of 
Guillain-Barré syndrome worldwide.A systematic literature 
review.Neuroepidemiology 2009;32(2):150–163. 
47. Rocha MS, Brucki SM, Carvalho AA, Lima UW. Epidemiologic features of 
Guillain-Barré syndrome in São Paulo, Brazil. Arq Neuropsiquiatr 
2004;62(1):33–37. 
66 
 
48. van Koningsveld R, Rico R, Gerstenbluth I, et al. Gastroenteritis associated 
Guillain-Barré syndrome on the Caribbean island Curaçao. Neurology 
2001;56(11):1467–1472. 
49. Hadden RDM, Cornblath DR, Hughes RAC, et al; Plasma 
Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. 
Electrophysiological classification of Guillain-Barré syndrome: clinical 
associations and outcome. Ann Neurol 1998;44(5):780–788. 
50. McKhann GM, Cornblath DR, Ho TW, et al. Clinical and electro 
physiological aspects of acute paralytic disease of children and young adults 
in northern China. Lancet 1991;338(8767):593–597. 
51. Kannan MA, Ch RK, Jabeen SA, Mridula KR, Rao P, Borgohain R. 
Clinical, electrophysiological subtypes and antiganglioside antibodies in 
childhood Guillain-Barré syndrome. Neurol India 2011;59(5):727–732. 
52. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. 
Arch Neurol 1986;43(11):1150–1152. 
53. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in 
Neurology. Guillain-Barré syndrome variants in Emilia-Romagna, Italy, 
1992-3: incidence, clinical features, and prognosis. J Neurol Neurosurg 
Psychiatry 1998;65(2):218–224. 
67 
 
54. Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain-Barré syndrome 
in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 
1997;63(4):494–500. 
55. Yuan CL, Wang YJ, Tsai CP. Miller Fisher syndrome: a hospital based 
retrospective study. Eur Neurol 2000;44(2):79–85. 
56. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher 
syndrome: case definitions and guidelines for collection, analysis, and 
presentation of immunization safety data. Vaccine 2011;29:599-612. 
57. Rostami AM. P2-reactive T cells in inflammatory demyelination of the 
peripheral nerve. J Infect Dis 1997;176: S160-163.  
58. Gabriel CM, Hughes RA, Moore SE, Smith KJ, Walsh FS. Induction of 
experimental autoimmune neuritis with peripheral myelin protein-22. Brain 
1998;121:1895-1902. 
59. Taylor JM, Pollard JD. Neurophysiological changes in demyelinating and 
axonal forms of acute experimental autoimmune neuritis in the Lewis rat. 
Muscle Nerve 2003;28:344-352. 
60. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune 
demyelinating disorders of the nervous system. Mol Med Today 2000;6:88-
91.  
68 
 
61. Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW. 
CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory 
diseases of the nervous system. J Neuroimmunol 2003;137:210-217. 
62. Kuwabara S. Guillain-Barre syndrome: epidemiology, pathophysiology and 
management. Drugs 2004;64:597-610. 
63. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. 
Advances in understanding and treatment of immune-mediated disorders of 
the peripheral nervous system. Muscle Nerve 2004;30:131-156. 
64. Yuki N, Odaka M. Ganglioside mimicry as a cause of Guillain-Barre 
syndrome. Curr Opin Neurol 2005;18:557-561. 
65. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. 
Carbohydrate mimicry between human ganglioside GM1 and 
Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. 
Proc Natl Acad Sci USA 2004;101:11404-11409. 
66. Yu RK, Usuki S, Ariga T. Ganglioside molecular mimicry and its 
pathological roles in Guillain-Barre syndrome and related diseases. Infect 
Immun 2006;74:6517-6527. 
67. Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy 
and acute motor-sensory axonal neuropathy share a common immunological 
profile. J Neurol Sci 1999;168:121-126. 
69 
 
68. Khalili-Shirazi A et al. Antiganglioside antibodies in Guillain-Barré 
syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg 
Psychiatry 1999;66:376–379. 
69. Koga M et al. Antiganglioside antibody in patients with Guillain-Barré 
syndrome who show bulbar palsy as an initial symptom. J Neurol Neurosurg 
Psychiatry 1999;66:513–516. 
70. Caudie et al. Ganglioside antibody profiles in 249 cases of Guillain-Barré 
Syndrome? Annales de Biologie Clinique 2002; 60(5):589-97. 
71. Menon A et al.Anti ganglioside antibody profile in Guillian Barry 
Syndrome.Do they indicate prognosis? Ann Ind Acad Neurol 2003;6:11-16. 
72. Hadden RD, Hughes RA. Management of inflammatory neuropathies. J 
Neurol Neurosurg Psychiatry 2003;74:9-14. 
73. Harel M, Shoenfeld Y. Intravenous immunoglobulin and Guillain-Barre 
syndrome. Clin Rev Allergy Immunol 2005;29:281-287. 
74. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations 
in the treatment of acute and chronic demyelinating neuropathies. Neurology 
2002;59(6):13-21. 
75. Finsterer J. Treatment of immune-mediated, dysimmune neuropathies. Acta 
Neurol Scand 2005;112:115-125. 
70 
 
76. Raphael JC. Present treatment of Guillain-Barre syndrome. Bull Acad Natl 
Med 2004;188:87-94. 
77. Nobile-Orazio E, Terenghi F. IVIg in idiopathic autoimmune neuropathies: 
analysis in the light of the latest results. J Neurol 2005;252(1):I7-13. 
78. Hughes RA, Wijdicks EF, Benson E, Cornblath DR, Hahn AF, Meythaler 
JM, et al; Multidisciplinary Consensus Group. Supportive care for patients 
with guillain-barre syndrome. Arch Neurol 2005;62:1194-1198. 
 
 
 
 
 
 
 
 
  
 
 
 
 
71 
 
ANNEXURES 
ANNEXURE I 
ABBREVIATIONS 
AIDP- Acute Inflammatory Demyelinating Polyradiculoneuropathy 
AMAN- Acute Motor Axonal Neuropathy 
AMSAN- Acute Motor Sensory Axonal Neuropathy 
CMAP- Compound Muscle Action Potential 
GBS- Guillain Barre Syndrome 
IVIg- Intravenous Immunoglobulin 
MFS- Miller Fisher Syndrome 
NCS- Nerve Conduction Study 
PE- Plasma Exchange 
SNAP- Sensory Nerve Action Potential 
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ANNEXURE II 
PATIENT CONSENT FORM 
 
Study Details:  Anti Ganglioside Antibody profile in GBS - Clinical                       
                            Immunological And Neurophysiological Significance 
Study Centre:  Rajiv Gandhi Government General Hospital,  
      Madras Medical College, Chennai - 600 003. 
 
Patient may check () these boxes: 
 
I confirm that I have understood the purpose of procedure for the above study. I have the 
opportunity to ask question and all my questions and doubts have been answered to my complete 
satisfaction. 
 
I understand that my participation in the study is voluntary and that I am free to withdraw at any 
time without giving reason, without my legal rights being affected. 
 
I understand that sponsor of the clinical study, others working on the sponsor‟s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health 
records, both in respect of current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties or published, unless 
as required under the law. I agree not to restrict the use of any data or results that arise from this 
study. 
 
I agree to take part in the above study and to comply with the instructions given during the study 
and faithfully cooperate with the study team and to immediately inform the study staff if I suffer 
from any deterioration in my health or well being or any unexpected or unusual symptoms. 
 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical (Serum CK) radiological, EMG, NCS and muscle biopsy, appropriate 
to the clinical diagnosis. 
 
 I hereby consent to participate in this study. 
 
 
Signature / Thumb impression: 
 
 
Patient Name and Address:          Place :                Date : 
 
 
Signature of Investigator 
 
 
Study Investigator‟s Name :                          Place :                Date : 
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ANNEXURE III 
 
INFORMATION SHEET 
 
 
 
 We are conducting a study of the “Anti Ganglioside Antibody profile in GBS - Clinical , 
Immunological And Neurophysiological Significance” at Institute of neurology, Rajiv Gandhi 
Government General Hospital, Chennai. The purpose of this study is to to investigate the 
prognostic value of the antiganglioside antibodies in GBS 
 The privacy of the patients in the research will be maintained throughout the study. In the event 
of any publication or presentation resulting from the research, no personally identifiable 
information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to participate in this study 
or to withdraw at any time; your decision will not result in any loss of benefits to which you are 
otherwise entitled.  
 The results of the special may be intimated to you at the end of the study period or during the 
study if anything is found abnormal which may aid in the management or treatment. 
 
 
 
 
Signature of Investigator                                            Signature of Participant 
 
 
Date: 
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ANNEXURE IV 
CASE PROFORMA 
ANTI GANGLIOSIDE ANTIBODY PROFILE IN GBS - CLINICAL, IMMUNOLOGICAL 
AND NEUROPHYSIOLOGICAL SIGNIFICANCE – CASE PROFORMA 
Name:  
Age/Sex: 
Address: 
 
 
Phone Number: 
 
Education: 
 
Occupation: 
 
Socio Economic Class (Modified Kuppuswamy Scale): 
I.UPPER 
II.UPPER MIDDLE 
III.LOWER MIDDLE 
IV.UPPER LOWER 
V.LOWER 
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CLINICAL DETAILS 
1.Chief Complaints: 
 
 
 
2.Duration of symptoms (in days): 
3.Antecedent illness: 
                  1.Yes 
                  2.No 
4.If Yes, 
                  1.Gastrointestinal 
                  2.Respiratory 
                  3.Others 
5. Interval between antecedent illness and onset of symptoms (in days): 
6. Associated Illness : 
                a.DM :  Yes / No 
                b.SHT : Yes / No 
                c.Alcoholism : Yes / No 
                d.Smoking : Yes / No 
                e.Hypothyroidism : Yes / No 
7. Vital Signs : 
                 PR :                              Single Breath Count : 
                 BP :                              Spo2 : 
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8. Neurological Examination : 
 HMF : 
 
Cranial Nerve Examination : 
 
 
Spino Muscular System : 
 Rt UL Rt LL Lt UL Lt LL 
Bulk     
Tone     
Power     
MRC SUM SCORE : 
Parts Right (x/5) Left(y/5) Total(x+y)/10 
Upper arm 
abductors 
   
Elbow flexors    
Wrist extensors    
Hip flexors 
 
   
Knee extensors    
 Foot dorsal 
flexors 
   
Total Score: Z/60 =                         
        
                     
Reflexes : 
 BJ TJ SJ KJ AJ Plantar 
Rt       
Lt       
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Sensory System : 
 
Autonomic Nervous System : 
 
The modified Hughes functional grading scale (f score): 
                        SCORE               FEATURES 
0 Healthy 
1 Minor symptoms or signs, able to run 
2 Able to walk 5 m independently 
3 Able to walk 5 m with a walker or 
support 
4 Bed- or chair-bound 
5 Requiring assisted ventilation 
6 Death 
 
 
Scale at admission: 
Scale at nadir: 
Scale at discharge: 
 
Treatment Received : 
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IvIg : 
Plasmapheresis : 
Mechanical Ventilation Duration : 
Others : 
Ganglioside Antibody Profile : 
Ab Intensity Result 
GM1   
GM2   
GM3   
GD1a   
GD1b   
GT1b   
GQ1b   
 
Nerve Conduction Study : 
CMAP Lat Amp CV F lat 
Rt Median     
Lt Median     
Rt Ulnar     
Lt Ulnar     
Rt Tibial     
Lt Tibial     
Rt Peroneal     
Lt Peroneal     
SNAP Lat Amp CV 
Rt Median    
Lt Median    
Rt Ulnar    
Lt Ulnar    
Rt Sural    
Lt Sural    
Interpretation: 
 
79 
 
Motor: 
 Median Ulnar Common Peroneal 
Prolonged DL    
Reduced CMAP 
amp 
   
Reduced NCV    
Absent or 
Prolonged F wave 
latency 
   
Inexcitable nerve    
 
 
 
Sensory: 
 Median Ulnar Sural 
Absent SNAP    
Reduced SNAP 
amp 
   
Reduced NCV    
 
 
FINAL DIAGNOSIS : 
1.AMAN 
2.AMSAN 
3.MFS 
4.AIDP 
5.MFS plus 
6.Other types
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ANNEXURE V 
MASTER CHART 
Name Age 
AGE 
DISTRIBUTION Age>30 SEX 
MK 
Scale Ant Inf 
Type of 
Inf Pre dur Bulbar  Auto Ophthal sensory 
Arukutty 54 0 1 1 2 0 0 0 0 0 0 0 
Balagurusamy 64 0 1 1 3 1 2 10 1 0 1 0 
Banumathi 51 0 1 2 2 1 2 14 0 0 0 1 
Ganesan 35 0 1 1 3 0 0 0 1 0 1 0 
Gunasekar 51 0 1 1 4 0 0 0 0 1 0 0 
Rani 55 0 1 2 3 0 0 0 0 1 0 0 
Sundar Raj 57 0 1 1 2 0 0 0 1 0 0 0 
Natarajan 48 0 1 1 3 0 0 0 0 0 0 0 
Nagammal 60 0 1 2 2 0 0 0 1 1 0 0 
Yuvaraj 30 1 0 1 3 1 2 10 1 1 0 0 
Suganya 20 1 0 2 4 1 1 10 1 0 0 0 
Annamalai 48 0 1 1 3 0 0 0 0 0 0 1 
Mukesh 37 0 1 1 3 0 0 0 1 0 0 0 
Nandhini 17 1 0 2 4 1 1 10 0 0 0 1 
Navaneetham 67 0 1 2 3 0 0 0 1 1 0 0 
Palraj 35 0 1 1 4 0 0 0 1 0 0 0 
Perumal 26 1 0 1 3 0 0 0 0 0 0 1 
Prakash 23 1 0 1 4 1 2 12 1 1 0 1 
Radhika 20 1 0 2 3 1 1 10 1 0 0 0 
Sigamani 45 0 1 1 4 0 0 0 1 1 0 1 
Rahman 28 1 0 1 3 1 1 12 1 0 0 0 
Satheesh 15 1 0 1 3 1 1 10 1 1 0 0 
Sathyaraj 25 1 0 1 4 1 1 10 1 0 0 1 
Sudhakar 20 1 0 1 4 0 0 0 0 0 0 0 
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Name Age 
AGE 
DISTRIBUTION Age>30 SEX 
MK 
Scale Ant Inf 
Type of 
Inf Pre dur Bulbar  Auto Ophthal sensory 
Suran raj 23 1 0 1 3 0 0 0 0 0 0 1 
Rajesh 17 1 0 1 4 1 1 10 1 1 0 1 
Sivaprakash 31 0 1 1 3 0 0 0 1 0 0 0 
Remosh khan 20 1 0 1 4 0 0 0 0 0 0 0 
Prema 55 0 1 2 5 1 2 10 1 0 0 0 
Neelakandan 30 1 0 1 4 0 0 0 0 0 0 1 
Nagenramma 43 0 1 2 5 0 0 0 0 0 0 0 
Amala 18 1 0 2 5 0 0 0 1 1 0 0 
Ashok kumar 55 0 1 1 4 0 0 0 1 1 0 0 
Karthik 37 0 1 1 5 0 0 0 0 0 0 0 
Nakammal 55 0 1 2 5 1 2 10 1 1 0 0 
Tamilarasi 56 0 1 2 5 1 2 12 1 0 0 0 
Kottishwari 24 1 0 2 4 0 0 0 0 0 0 0 
Vijayalaxmi 69 0 1 2 5 0 0 0 1 0 0 0 
Bosa durai 40 0 1 1 5 0 0 0 1 0 0 0 
Thilagan 24 1 0 1 5 0 0 0 1 0 0 0 
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Dur 
Peek 
Dur PK 
<7 
Ven
ti 
IvI
g 
P
P 
Rec
ov 
Recov4
wk 
MRC 
Adm 
MRCAd<
30 
MRC 
Ds 
Hugh 
adm 
Hugh 
Ds 
Pro
DL 
Red 
CMAP 
Red 
CV 
Pro 
F 
Inex 
Ner 
14 0 0 0 0 22 1 50 0 56 3 2 1 0 1 1 0 
4 1 1 1 0 42 0 0 1 48 4 3 1 1 0 1 0 
8 0 0 1 0 14 1 32 0 48 4 3 1 1 1 1 0 
5 1 1 0 1 42 0 12 1 48 5 3 1 1 1 1 0 
4 1 1 1 1 44 0 0 1 48 5 3 0 0 0 1 1 
4 1 1 0 1 42 0 12 1 48 5 3 1 0 1 1 0 
4 1 1 0 1 48 0 12 1 48 5 3 0 0 0 0 1 
8 0 0 1 0 21 1 34 0 48 4 3 1 1 1 1 0 
4 1 1 1 0 40 0 12 1 42 5 4 1 0 0 1 0 
7 1 1 1 1 42 0 12 1 40 5 4 1 0 1 1 0 
6 1 1 1 0 48 0 12 1 44 5 3 1 1 1 1 0 
8 0 0 0 1 24 1 46 0 52 4 3 1 1 0 1 0 
6 1 0 0 1 42 0 24 1 48 4 3 1 1 1 1 0 
8 0 1 1 1 52 0 52 0 32 5 4 0 0 0 0 1 
7 1 1 1 0 56 0 12 1 48 5 4 1 0 1 1 0 
4 1 0 1 0 42 0 24 1 52 4 3 1 1 1 1 0 
8 0 0 0 0 21 1 52 0 46 4 3 1 1 0 1 0 
6 1 1 1 1 44 0 12 1 42 5 4 0 0 0 1 1 
4 1 0 0 1 42 0 24 1 42 4 3 1 0 1 1 0 
6 1 1 1 1 62 0 12 1 32 5 4 0 0 0 1 1 
7 1 0 0 1 32 0 24 1 44 4 3 1 1 1 1 0 
7 1 1 1 0 32 0 24 1 42 4 3 1 0 1 1 0 
6 1 1 1 1 54 0 12 1 34 5 4 0 0 0 0 1 
8 0 1 0 1 24 1 12 1 46 4 3 1 1 0 1 0 
6 1 0 1 0 21 1 32 0 44 4 3 1 1 1 1 0 
5 1 1 1 1 42 0 24 1 42 5 4 0 0 0 0 1 
7 1 0 1 0 34 0 12 1 54 4 3 1 0 1 1 0 
8 0 0 1 0 32 0 24 1 52 4 3 1 0 1 1 0 
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Dur 
Peek 
Dur PK 
<7 
Ven
ti 
IvI
g 
P
P 
Rec
ov 
Recov4
wk 
MRC 
Adm 
MRCAd<
30 
MRC 
Ds 
Hugh 
adm 
Hugh 
Ds 
Pro
DL 
Red 
CMAP 
Red 
CV 
Pro 
F 
Inex 
Ner 
6 1 1 1 0 42 0 12 1 42 5 3 1 0 1 1 0 
8 0 0 1 0 21 1 32 0 44 5 3 1 1 1 1 0 
10 0 0 1 0 22 1 42 0 48 4 3 1 0 0 1 0 
6 1 1 1 0 35 0 12 1 52 4 3 1 1 1 1 0 
4 1 1 0 1 32 0 24 1 52 4 3 1 1 0 1 0 
6 1 0 1 0 24 1 34 0 46 4 3 1 1 1 1 0 
6 1 1 1 0 42 0 32 0 42 5 4 1 1 1 1 0 
4 1 1 1 0 44 0 12 1 34 5 4 1 0 1 1 0 
9 0 0 1 0 21 1 38 0 42 4 3 1 0 1 1 0 
7 1 0 0 1 32 0 12 1 54 4 3 1 0 1 1 0 
4 1 1 1 0 42 0 12 1 34 5 4 1 1 1 1 0 
6 1 0 1 0 32 0 24 1 52 4 3 1 1 1 1 0 
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Abs SNAP Red SNAP Red CV GM1 GM2 GM3 GD1a GD1b GT1b GQ1b Diag Ab Pos 
1 1 1 0 0 0 0 0 0 0 4 0 
0 0 0 0 0 0 0 0 0 1 3 1 
0 0 0 0 0 0 0 0 0 0 2 0 
0 0 0 0 0 0 0 0 0 1 3 1 
0 0 0 1 0 0 0 0 0 0 1 1 
1 1 1 1 1 0 0 0 0 0 4 1 
0 0 0 1 1 0 0 0 0 0 1 1 
0 0 0 0 0 0 0 0 0 0 1 0 
1 1 1 0 0 0 1 0 0 0 4 1 
1 1 1 0 1 1 1 1 0 0 4 1 
0 0 0 0 0 1 0 0 0 0 1 1 
1 1 1 0 0 0 0 0 0 0 2 0 
0 0 0 1 1 1 0 0 0 0 1 1 
0 0 0 0 0 0 0 0 0 0 2 0 
1 1 1 1 1 0 0 0 0 0 4 1 
0 0 0 1 1 0 0 0 0 0 1 1 
1 1 1 0 0 0 0 0 0 0 2 0 
0 0 0 1 1 0 0 0 0 0 2 1 
0 0 0 1 1 0 0 0 0 0 4 1 
0 0 0 0 0 0 1 0 0 0 2 1 
0 0 0 1 1 0 0 0 0 0 1 1 
0 0 0 1 1 0 0 0 0 0 4 1 
0 0 0 0 1 1 0 0 0 0 2 1 
0 0 0 1 1 0 0 0 0 0 1 1 
1 1 1 0 0 0 0 0 0 0 2 0 
0 0 0 0 0 1 0 0 0 0 2 1 
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Abs SNAP Red SNAP Red CV GM1 GM2 GM3 GD1a GD1b GT1b GQ1b Diag Ab Pos 
1 1 1 1 1 0 0 0 0 0 4 1 
0 0 0 1 1 0 0 0 0 0 4 1 
0 0 0 0 1 1 0 0 0 0 4 1 
1 1 1 0 0 0 0 0 0 0 2 0 
1 1 1 0 0 0 0 0 0 0 4 0 
0 0 0 0 1 1 0 0 0 0 1 1 
1 1 1 0 1 1 0 0 0 0 4 1 
0 0 0 0 0 0 0 0 0 0 1 0 
0 0 0 0 0 0 1 0 0 0 1 1 
0 0 0 0 1 1 1 0 0 0 4 1 
1 1 1 0 0 0 0 0 0 0 4 0 
1 1 1 0 0 1 1 0 0 0 4 1 
0 0 0 0 0 1 0 1 1 0 1 1 
1 1 1 1 1 1 0 0 0 0 1 1 
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ANNEXURE VI 
ETHICAL COMMITTEE APPROVAL SHEET 
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ANNEXURE VII 
TURNITIN-PLAGIARISM SCREEN SHOT 
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TURNITIN-DIGITAL RECEIPT 
 
 
